Jonathan Serody, MD, explains in a two-minute video the action behind chimeric antigen T-cell, or CAR-T, immunotherapy and how UNC Lineberger is designing, developing and delivering CAR-T therapies to treat cancers that fail to respond to standard treatments.
UNC Lineberger is one of only a select few academic centers in the United States – and the only center in North Carolina, Georgia, South Carolina, Tennessee and Virginia – with the scientific, technical and clinical capabilities to identify new tumor targets and then develop and infuse novel CAR-T immunotherapy. These therapies are manufactured at UNC Lineberger and are not commercially available. This makes it possible for people who live in or near the Southeastern U.S. to stay closer to home to undergo clinical immunotherapy treatment for cancer.